-
Mashup Score: 52Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer - 10 day(s) ago
This randomized clinical trial evaluates the efficacy and safety of first-line toripalimab vs placebo plus etoposide and platinum-based chemotherapy for treating patients with extensive-stage small cell lung cancer.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 42
The efficacy and safety of sotorasib plus platinum-doublet chemotherapy in KRAS G12C-mutated non-squamous non-small cell lung cancer (non-Sq NSCLC) were previously reported with limited follow-up period.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Ph II SCARLET trial of sotorasib/carbo/pemetrexed in 1L KRAS G12C+ @JTOonline: - 30pts - ORR 88.9% mPFS 6.6m mOS 20.6m - p53, EGFR, METamp identified on plasma, at time of acq resistance Interesting, somewhat controversial to omit IO here @OncoAlert #LCSM https://t.co/rqIcY07evO
-
-
Mashup Score: 20Impact of comorbidities on the mortality benefits of lung cancer screening: a post-hoc analysis of PLCO and NLST trials - 14 day(s) ago
To evaluate how comorbidities affect mortality benefits of lung cancer screening (LCS) with low-dose computed-tomography (LDCT).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Interesting study shows PLCO-ci’ (co-morbidity) index improves pt selection for lung cancer screening @JTOonline - ⬇️LC mortality in pts with intermediate comorbidity (Q2-Q3-Q4) HR 0.62; 0,68; 0.72 - But not in pts with low/high PLCO-ci @OncoAlert #LCSM https://t.co/w17MyQ0Dxx
-
-
Mashup Score: 1In Brief for January 8, 2025 - ILCN.org (ILCN/WCLC) - 14 day(s) ago
The US FDA approves ensartinib for ALK-positive NSCLC and provides an updated regulatory review of subcutaneous amivantamab.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
ICYMI: The US FDA approves ensartinib for ALK-positive NSCLC and provides an updated regulatory review of subcutaneous amivantamab. More updates in ILCN: https://t.co/g5vcoT9ktr #LCSM
-
-
Mashup Score: 2Unmet Needs and Future Perspectives of RET-Positive NSCLC - 14 day(s) ago
Panelists discuss the unmet needs and future perspectives in the treatment of RET-positive non–small cell lung cancer (NSCLC), focusing on areas for improvement in therapy and the potential for new treatment strategies.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
.@RETpositive @RetRenegades #LCSM https://t.co/QDwYrt3mtP via @onclive
-
-
Mashup Score: 2
The NeXT Personal platform identified minuscule amounts of ctDNA that were found to be predictive of OS and RFS outcomes in patients with lung adenocarcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
ctDNA status was predictive of OS in patients with lung adenocarcinoma (ctDNA low: HR, 11.08, 95% CI, 1.48-83.2; ctDNA high: HR, 19.33; 95% CI, 2.56-146.0) and RFS (low: HR, 14.17, 95% CI, 1.91–105.3; high: HR, 25.79, 95% CI, 3.48–191.4). #lcsm https://t.co/kjd7gin6Cm
-
-
Mashup Score: 4Nivolumab, Ipilimumab With or Without Chemotherapy Shows Benefit in Metastatic NSCLC | Docwire News - 14 day(s) ago
Nivolumab and ipilimumab, with or without chemotherapy, showed a “long-term, durable clinical benefit” for metastatic NSCLC, according to CheckMate 227 and CheckMate 9LA studies.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📋 Nivolumab plus ipilimumab with or without chemotherapy shows a "long-term, durable clinical benefit" in patients with mNSCLC and PD-L1 <1%, according to an analysis of CheckMate 227 & CheckMate 9LA by @peters_solange & colleagues. ➡️ Read more: https://t.co/3G56EPRZad #lcsm https://t.co/pAiTdjHvHe
-
-
Mashup Score: 4Research to Watch: Lurbinectedin-Atezolizumab Combination Demonstrates Significant OS, PFS Benefits - ILCN.org (ILCN/WCLC) - 15 day(s) ago
Promising results from the phase III IMforte trial reveal a potential first-line therapy for patients with ES-SCLC.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
Promising results from the phase III IMforte trial reveal a potential first-line therapy for patients with ES-SCLC. Find out more in ILCN: https://t.co/vR7P0lRUOt #LCSM
-
-
Mashup Score: 18
The advocacy Women Against Lung Cancer in Europe (WALCE) promoted the European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) and provided a free-of-charge molecular profiling platform for NSCLC sample characterization with the aim of increasing the detection of targetable drivers and improving patients’ access to clinical trials in Europe.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
Women Against Lung Cancer in Europe promoted EPROPA to reduce the gap between relevant heterogeneity of molecular testing & cancer care. This program aimed to improve patient access to clinical trials by providing free-of-charge molecular profiling. https://t.co/6yUR9Plbj9 #LCSM https://t.co/JEJtIAodz5
-
-
Mashup Score: 4
During the opening plenary session at the 2024 Asia Conference on Lung Cancer, experts offered their perspectives on clinical trials, combination therapies, and research initiatives.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
Delve into highlights from the opening plenary session at the 2024 Asia Conference on Lung Cancer. Visit ILCN for more details: https://t.co/fdnJfMuXPh #LCSM
-
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer https://t.co/MhWo1dWx2z #lcsm